NeuroDerm Ltd.
Neuroderm is an agile, entrepreneurial R&D company dedicated to driving healthcare innovation and patient-centric solutions through Pharma & MedTech integration. Its mission is to reduce disease burden and improve quality of life for patients and their families by developing next-generation drug-device combination therapies for central nervous system disorders, especially Parkinson's disease. The company is a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation, with a global presence in Japan, the US, and Europe.
Industries
Nr. of Employees
medium (51-250)
NeuroDerm Ltd.
3 Haim Pekeris Street, Ruhrberg Science Bldg. Bell Entrance, 4th floor, Rehovot 7670212, Israel
Patents
Products
ND0612 — continuous subcutaneous levodopa/carbidopa infusion system
An integrated therapy comprising a liquid levodopa/carbidopa formulation delivered via a portable, self-administered continuous subcutaneous infusion system, intended to maintain steady plasma levodopa concentrations and reduce motor fluctuations.
ND0612 — continuous subcutaneous levodopa/carbidopa infusion system
An integrated therapy comprising a liquid levodopa/carbidopa formulation delivered via a portable, self-administered continuous subcutaneous infusion system, intended to maintain steady plasma levodopa concentrations and reduce motor fluctuations.
Services
End-to-end in-house development combining pharmaceutical formulation, device engineering, and digital health elements for continuous infusion therapies, delivered via internal teams and external partnerships as needed.
Design and execution of clinical programs across Phase I–III and long-term safety studies, including pharmacology, PK, efficacy and safety assessments.
Preparation and management of regulatory submissions and interactions with major regulatory authorities for combination products.
Pharmaceutical development, process development, technology transfer, and coordination with CMOs to scale formulations and device manufacturing.
Quality assurance, release testing and compliance activities covering preclinical, clinical and manufacturing stages for drug-device products.
Management of technology transfer processes, outsourced manufacturing relationships and supply chain operations to support product commercialization.
End-to-end in-house development combining pharmaceutical formulation, device engineering, and digital health elements for continuous infusion therapies, delivered via internal teams and external partnerships as needed.
Design and execution of clinical programs across Phase I–III and long-term safety studies, including pharmacology, PK, efficacy and safety assessments.
Preparation and management of regulatory submissions and interactions with major regulatory authorities for combination products.
Pharmaceutical development, process development, technology transfer, and coordination with CMOs to scale formulations and device manufacturing.
Quality assurance, release testing and compliance activities covering preclinical, clinical and manufacturing stages for drug-device products.
Management of technology transfer processes, outsourced manufacturing relationships and supply chain operations to support product commercialization.
Expertise Areas
- Drug–device combination development
- Clinical trial management (Phases I–III, long-term safety)
- Pharmaceutical formulation development for parenteral delivery
- Device design and production scale-up
Key Technologies
- Continuous subcutaneous infusion
- Liquid parenteral formulation of levodopa/carbidopa
- Portable infusion pump engineering
- Drug–device integration platforms
News & Updates
On May 29, 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ND0612.
On Feb 21, 2025, the European Medicines Agency (EMA) accepted for review the marketing authorization application (MAA) for ND0612.
On Mar 18, 2024, NeuroDerm announced positive results from its Phase 3 BouNDless trial, published in The Lancet Neurology.
Data showed favorable efficacy of ND0612 compared to oral immediate-release levodopa/carbidopa.
On May 29, 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ND0612.
On Feb 21, 2025, the European Medicines Agency (EMA) accepted for review the marketing authorization application (MAA) for ND0612.
On Mar 18, 2024, NeuroDerm announced positive results from its Phase 3 BouNDless trial, published in The Lancet Neurology.
Data showed favorable efficacy of ND0612 compared to oral immediate-release levodopa/carbidopa.